-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 01-18-2026 TO 01-24-2026
We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock quote page…
$ABBV, $AZN, $ELDN, $GMAB, $GNLX, $LLY, $LTRN, $MNKD, $NOV, $NVO, $NVS, $PFE, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
Sanofi’s $2.2 Billion Bet: What Their Acquisition of an HBV Vaccine Maker Means for Global Health
NASDAQ: $SNY In a move that sent ripples through the pharmaceutical landscape, Sanofi recently announced its acquisition of a Hepatitis B (HBV) vaccine maker for a staggering $2.2 billion. This strategic purchase, detailed in a recent article from Pharmaceutical Technology, isn’t just a financial transaction; it represents a significant investment in global public health and…